Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Neuroblastoma 5Recurrence 2Multiple Myeloma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Transplant-Related Hematologic Malignancy 1Stomatitis 1Oligodendroglioma 1Neoplasms 1Nasopharyngeal Carcinoma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Carcinoma, Intraductal, Noninfiltrating 1Brain Neoplasms 1

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT05544968 2026-04-03

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Medical College of Wisconsin

Phase 1 Recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
22 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡